Back to mobile site

Amarin (AMRN) Could Get FDA Catalysts By Year-End, Says Leerink Swann

August 9, 2013 10:59 AM EDT Send to a Friend
Leerink Swann maintained an Outperform rating on Amarin Corporation (NASDAQ: AMRN) and adjusted its price target to $18.00 (from $20.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login